News & Updates

The T-cell-redirecting bispecific antibody teclistamab induced deep and durable responses in patients with triple-class-exposed relapsed or refractory multiple myeloma (R/R MM), findings from the phase I/II MajesTEC-1 trial have shown.

Higher preoperative vitamin B6 status appears to improve the overall survival (OS) of patients with stage I‒III colorectal cancer (CRC), suggests a recent study.

There appears to be a twin-peak prevalence profile (TPP) for diseases of the stomach, including Helicobacter pylori (Hp) infection, gastric cancer (GC), gastric intraepithelial neoplasia (GIN), and gastritis, according to a recent China study. The first peak typically occurs during middle-adulthood while the second peak happens in late life.

Women who eat cured meat appear to be at heightened risk of developing breast cancer, according to a study from Hong Kong.

The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.

The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.